Skip to main
CLYM

CLYM Stock Forecast & Price Target

CLYM Analyst Ratings

Based on 4 analyst ratings
Buy
Strong Buy 50%
Buy 50%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Climb Bio Inc. has raised its peak worldwide patient estimates for its therapeutic candidate budoprutug to 15,500, indicating a significant market opportunity and corresponding peak sales potential of $1.8 billion due to the lack of competition in CD19-targeted treatments for pMN. The company's recent acquisition of Tenet Medicines, along with a $120 million private investment in public equity (PIPE), has notably enhanced its valuation, positioning Climb Bio favorably for future growth. Additionally, positive clinical data from both budoprutug and CLYM116 may drive substantial equity value appreciation, paralleling the value inflection seen with similar companies in the biotechnology sector.

Bears say

Climb Bio Inc has never achieved profitability, which raises concerns regarding its financial sustainability and ability to fund ongoing and future clinical trials. Additionally, there are significant risks associated with the advancement of its product candidates, specifically budoprutug and CLYM116, which may face challenges in clinical development and securing regulatory approvals. The company is also exposed to partnership risks and potential dilution, further complicating its financial outlook amidst the backdrop of underperforming competitors and clinical trials with uncertain outcomes.

CLYM has been analyzed by 4 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 50% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Climb Bio Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Climb Bio Inc (CLYM) Forecast

Analysts have given CLYM a Buy based on their latest research and market trends.

According to 4 analysts, CLYM has a Buy consensus rating as of Feb 7, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $9.50, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $9.50, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Climb Bio Inc (CLYM)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.